NSCLC remains the leading cause of cancer-related mortality worldwide, with EGFR mutations being a critical driver in approximately 10-15% of lung adenocarcinomas in Western populations, and up to 40% ...
The identification of all potential EGFR driver mutations is especially critical for patients with lung adenocarcinoma from East Asia or of Asian descent because of the prevalence of such mutations ...
Understanding the patterns of acquired resistance to epidermal growth factor receptor (EGFR) TKI treatment has led to more effective combination therapy and continues to drive development of novel ...
Introduction of a Differentiated Bispecific Nano ADC Positioned to Compete in Major Global Oncology Markets BOSTON, MA, ...
Patients with EGFR-mutated non-small cell lung cancer (NSCLC) who progressed on first-line osimertinib (Tagrisso) had better progression-free survival (PFS) in second line when they continued ...
Merus has reported a 79% 12-month survival rate in cancer patients on its bispecific antibody, cementing William Blair analysts' belief the candidate has a “best-in-disease profile.” The bispecific ...
EGFR-positive lung cancer is more common in non-smokers (particularly those with adenocarcinoma) and younger adults, as it often develops from a single genetic mutation rather than widespread DNA ...
Transformative clinical pipeline transaction will add CL-273, a pan-EGFR inhibitor, and CL-741, a Phase 1-Ready c-MET inhibitor, to Kairos Pharma's clinical portfolio to target multi-billion dollar ...
Cell signaling is crucial for cells to communicate and function correctly. Disruptions in these pathways, caused by genetic mutations or environmental factors, can lead to uncontrolled cell growth, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results